Journals / Cukurova Medical Journal / 2020 / Cilt: 45 - Sayı: 2

Growth parameters of Turkish children with juvenile idiopathic arthritis

Juvenil idiopatik artritli Türk çocukların büyüme parametreleri

Pages
495–501
Publication Date
2020-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Suppressing ongoing inflammation in JIA patients improves both weight and BMI z-scores of those patients, however, it may be insufficient to prevent short stature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood which could results in growth retardation.
📊
Key Findings & Data:Materials and Methods: Clinical and laboratory data, weight, height, and body mass index of 233 JIA patients were retrospectively collected from medical files.
💡
Conclusion & Impact:Conclusion: Suppressing ongoing inflammation in JIA patients improves both weight and BMI z-scores of those patients, however, it may be insufficient to prevent short stature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Büyüme · çocuk · juvenile idiopatik artrit

Abstract

Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood which could results in growth retardation. With the present study, we aimed to investigate the growth parameters in Turkish children with JIA. Materials and Methods: Clinical and laboratory data, weight, height, and body mass index of 233 JIA patients were retrospectively collected from medical files. Growth parameters and z-scores were calculated by anthropometric references in Turkish children. The patients were diagnosed according to the International League of Associations for Rheumatology classification criteria.Results: The frequency of female patients was 59.2% (138). The mean age at diagnosis was 7.40±4.54 years, the mean age at the study time was 11.20±4.45 years. While mean initial visit weight and BMI z-scores were significantly improved at last visit, initial mean height z-score was significantly decreased. The frequency of short stature at last visit was 7.3% (number, 17). Acute phase reactants, including erythrocyte sedimentation rate, C-reactive protein levels were significantly lower at last visit than initial. Last visit growth parameters did not differ according age at diagnosis, disease duration and presence or absence of remission, relapses, corticosteroid usage, and biologic agent usage. Conclusion: Suppressing ongoing inflammation in JIA patients improves both weight and BMI z-scores of those patients, however, it may be insufficient to prevent short stature.

Özet

Amaç: Juvenil idiopatik artrit (JIA) çocukluk çağında en sık görülen romatizmal hastalıktır ve büyüme geriliği ile sonuçlanabilmektedir. Bu çalışma ile JIA’lı Türk çocuklarında büyüme parametrelerini araştırmayı amaçladık. Gereç ve Yöntem: Juvenil idiopatik artrit tanılı 233 hastanın klinik ve laboratuvar verileri, vücut ağırlığı, boy ve vücut kitle indeksi (VKI) bilgileri hastaların tıbbi dosyalarından geriye dönük elde edildi. Büyüme verileri ve z-skorları Türk çocuklarının antropometrik referans değerlerine göre hesaplandı. Hastalara International League of Associations for Rheumatology sınıflama kriterlerine göre tanı kondu. Bulgular: Hastaların %59,2’si (sayı, 138) kız hastaydı. Ortalama tanı yaşı 7.40±4,54 yıl ve çalışma esnasında ortalama yaş 11.20±4,45 yıldı. Ortalama ilk vizit vücut ağırlığı ve VKI z-skorları son vizit değerlere göre istatistiksel anlamlı olarak düzeldi. Ortalama ilk vizit boy z-skoru ise istatistiksel anlamlı olarak geriledi. Son vizitte kısa boy sıklığı %7,3 (sayı, 17) idi. Eritrosit çökelme hızı, C-reaktif protein düzeyleri dahil olmak üzere akut faz reaktanları son vizitte ilk vizit değerlerine kıyasla anlamlı olarak düşüktü. Son vizit büyüme parametreleri tanı yaşı, hastalık süresi, remisyon ve relaps durumu, kortikosteroid ve biyolojik ajan kullanımına göre farklılık göstermemekteydi. Sonuç: JIA hastalarında devam eden inflamasyonun kontrol altına alınması ile vücut ağırlığı ve VKI z-skorları düzelebilir, fakat bu durum boy kısalığını önlemek için yeterli olmayabilir.

🔖

Cite This Article

BALCI, S., ÇALKAN, M., DİLEK, S. Ö., DOĞRUEL, D., ALTİNTAS, D., EKİNCİ, R. M. K. (2020). Growth parameters of Turkish children with juvenile idiopathic arthritis. Cukurova Medical Journal, Cilt: 45 - Sayı: 2, 495–501. https://ajindex.com/articles/56168

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Yilmaz M, Kendirli SG, Altintas DU, Karakoc GB, Inal A, Kilic M. Juvenile idiopathic arthritis profile in Turkish children. Pediatr Int. 2008;50:154-8
  2. Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile idiopathic arthritis. Balkan Med J. 2017;34:90-101
  3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2
  4. MacRae VE, Wong SC, Farquharson C, Ahmed SF. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med. 2006;18:1011-8
  5. Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int. 2014;34:1483-8
  6. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290-4
  7. Neyzi O, Gunoz A, Furman A, Bundak R, Gökçay G, Darendeliler F et al. Türk Çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hastalıkları Derg 2008;51:1-14
  8. Balci S, Ekinci RMK, Bayazit AK, Melek E,Dogruel D, Altintas DU et al. Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey. Clin Rheumatol. 2019;38:1459-68
  9. Kişla Ekinci RM, Balci S, Akay E, Doğruel D, Altintaş DU, Yilmaz M. Disease severity and genotype affect physical growth in children with familial mediterranean fever. Arch Rheumatol. 2019;34:288- 93
  10. Gaspari S, Marcovecchio ML, Breda L, Chiarelli F. Growth in juvenile idiopathic arthritis: the role of inflammation. Clin Exp Rheumatol. 2011;29:104-110
  11. De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67:840-8
  12. Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR; British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rh